BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35935852)

  • 1. The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Luo X; Zhou Z; Zeng X; Liu Q
    Front Pharmacol; 2022; 13():935581. PubMed ID: 35935852
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China.
    Zhou D; Luo X; Zhou Z; Zeng X; Wan X; Tan C; Liu Q
    Front Pharmacol; 2022; 13():880280. PubMed ID: 36091746
    [No Abstract]   [Full Text] [Related]  

  • 3. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.
    Shi Y; Qian D; Li Y; Chen W; Bo M; Zhang M; Shi J; Jia B; Dai Y; Li G
    Transl Cancer Res; 2023 Apr; 12(4):928-938. PubMed ID: 37180653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.
    Zhang H; Li L; Feng L; Zhou Z; Zhang X; Feng J; Liu Q
    Adv Ther; 2023 Nov; 40(11):4945-4956. PubMed ID: 37715852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
    Shi Y; Pei R; Liu S
    Front Oncol; 2022; 12():833773. PubMed ID: 36324594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Liu Y; Shao R
    Front Pharmacol; 2024; 15():1225076. PubMed ID: 38813103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China.
    Liu H; Wang Y; He Q
    Health Econ Rev; 2022 Dec; 12(1):66. PubMed ID: 36581793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer.
    Pei Z; Xiao N; Yang P
    Front Pharmacol; 2023; 14():1265784. PubMed ID: 37964872
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
    He C; Mi X; Xu G; Xu X; Xin W; Zhong L; Zhu J; Shu Q; Fang L; Ding H
    PLoS One; 2024; 19(5):e0302961. PubMed ID: 38748691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
    Liu G; Kang S; Wang X; Shang F
    Front Oncol; 2021; 11():669195. PubMed ID: 33987103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
    Zhao M; Shao T; Chi Z; Tang W
    Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
    Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
    Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
    Wu B; Lu S
    Transl Lung Cancer Res; 2020 Oct; 9(5):1770-1784. PubMed ID: 33209600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
    Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
    BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.
    Zhou C; Wei J; Xu K; Lin Y; Zhang L; Li X
    Risk Manag Healthc Policy; 2023; 16():2447-2458. PubMed ID: 38024498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K
    Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
    Huo G; Liu W; Kang S; Chen P
    Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
    Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
    Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.